<code id='66C607DA75'></code><style id='66C607DA75'></style>
      • <acronym id='66C607DA75'></acronym>
      <center id='66C607DA75'><center id='66C607DA75'><tfoot id='66C607DA75'></tfoot></center><abbr id='66C607DA75'><dir id='66C607DA75'><tfoot id='66C607DA75'></tfoot><noframes id='66C607DA75'>
      • <optgroup id='66C607DA75'><strike id='66C607DA75'><sup id='66C607DA75'></sup></strike><code id='66C607DA75'></code></optgroup>
        5. <b id='66C607DA75'><label id='66C607DA75'><select id='66C607DA75'><dt id='66C607DA75'><span id='66C607DA75'></span></dt></select></label></b><u id='66C607DA75'></u>
          <i id='66C607DA75'><strike id='66C607DA75'><tt id='66C607DA75'><pre id='66C607DA75'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-30 04:29:26 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：2273
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          5 takeaways from STAT's examination of Zynex Medical
                                
                            
          Next article：  
                                      
                                          Novavax promises a turnaround & Lilly roils the obesity market
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles